Related references
Note: Only part of the references are listed.Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood
Maja-Theresa Dieterlen et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2012)
Present and Future of Immunosuppressive Therapy in Kidney Transplantation
C. Ponticelli
TRANSPLANTATION PROCEEDINGS (2011)
Silymarin Inhibits In Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection
Chihiro Morishima et al.
GASTROENTEROLOGY (2010)
Resveratrol Inhibits mTOR Signaling by Promoting the Interaction between mTOR and DEPTOR
Meilian Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation
Marianna Esposito et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Silymarin suppress CD4+T cell activation and proliferation: Effects on NF-κB activity and IL-2 production
Marjan Gharagozloo et al.
PHARMACOLOGICAL RESEARCH (2010)
Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor Complex
Christopher S. Beevers et al.
CANCER RESEARCH (2009)
Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy
P. Garcia-Maceira et al.
ONCOGENE (2009)
The multiple facets of mTOR in immunity
Thomas Weichhart et al.
TRENDS IN IMMUNOLOGY (2009)
Immunoregulatory functions of mTOR inhibition
Angus W. Thomson et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-Cells
Paolo Monti et al.
DIABETES (2008)
Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis
Kyungwon Min et al.
ARCHIVES OF PHARMACAL RESEARCH (2007)
Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells
Marjan Gharagozloo et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Targeting mammalian target of rapamycin (mTOR) for health and diseases
Chi Kwan Tsang et al.
DRUG DISCOVERY TODAY (2007)
Silybin and silymarin - New and emerging applications in medicine
Radek Gazak et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/Akt signaling pathways
Qunzhou Zhang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus
David Fernandez et al.
ARTHRITIS AND RHEUMATISM (2006)
Silibinin protects mice from T cell-dependent liver injury
J Schümann et al.
JOURNAL OF HEPATOLOGY (2003)
Share Paper
